

LIFE SAVING DRUGS PROGRAM EXPERT PANEL  
NINTH MEETING: 17 June 2021

**AGENDA**

**1. Standing business**

- 1.1. Welcome & apologies
- 1.2. Declaration of potential or actual Conflict of Interest
- 1.3 Correspondence
- 1.4 Report from the Secretariat

**2. 24-month Reviews**

- 2.1 Cerliponase (Brineura®) for the treatment of Late-Infantile Onset Batten disease (CLN2)
- 2.2 Migalastat (Galafold®) for the treatment of Fabry disease

**3. Managed Access Program**

- 3.1. Elosulfase alfa (Vimizim®) for the treatment of Mucopolysaccharidosis Type IV-A (MPS IVA)

**4. Other business**